Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Ponikowski, Piotr"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 212
Tytuł:
Sex-stratified patterns of emergency cardiovascular admissions prior and during the COVID-19 pandemic.
Autorzy:
Gajewski P; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland. dr.piotr..
Błaziak M; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Urban S; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Garus M; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Braunschweig F; Department of Medicine, Department of Cardiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Caldeira D; Cardiovascular da Universidade de Lisboa - CCUL (), CEMBE, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.; Cardiology Department, Hospital Universitário de Santa Maria (CHLN), Centro Académico de Medicina de Lisboa (CAML), Lisbon, Portugal.
Gawor A; Student Scientific Organization, Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Greenwood JP; Leeds University and Leeds Teaching Hospitals NHS Trust, Leeds,, UK.
Guzik M; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Halfwerk FR; Thorax Center Twente, Medisch Spectrum Twente, Enschede, The Netherlands.
Iwanek G; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Jarocki M; Student Scientific Organization, Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Jura M; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Krzystek-Korpacka M; Department of Medical Biochemistry, Wroclaw Medical University, Wrocław, Poland.
Lewandowski Ł; Department of Medical Biochemistry, Wroclaw Medical University, Wrocław, Poland.
Lund LH; Department of Medicine, Department of Cardiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Matysiak M; Student Scientific Organization, Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Pinto F; Cardiovascular da Universidade de Lisboa - CCUL (), CEMBE, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.; Cardiology Department, Hospital Universitário de Santa Maria (CHLN), Centro Académico de Medicina de Lisboa (CAML), Lisbon, Portugal.
Sleziak J; Student Scientific Organization, Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Wietrzyk W; Student Scientific Organization, Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Sokolski M; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Biegus J; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Zymliński R; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Oct 20; Vol. 13 (1), pp. 17924. Date of Electronic Publication: 2023 Oct 20.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
COVID-19*/epidemiology
ST Elevation Myocardial Infarction*/epidemiology
Acute Coronary Syndrome*/epidemiology
Heart Failure*/epidemiology
Pulmonary Embolism*/epidemiology
Male ; Humans ; Female ; Pandemics ; SARS-CoV-2
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial.
Autorzy:
Rosano G; Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele, Rome, Italy. .
Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.; Institute of Heart Diseases, University Hospital, Wroclaw, Poland.
Vitale C; Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele, Rome, Italy.
Anker SD; Department of Cardiology (CVK) of German Heart Center Charité; Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Butler J; Baylor Scott and White Research Institute, Dallas, TX, USA.; University of Mississippi, Jackson, MS, USA.
Fabien V; CSL Vifor, Glattbrugg, Switzerland.
Filippatos G; National and Kapodistrian University of Athens Medical School, Athens University Hospital Attikon, Athens, Greece.
Kirwan BA; Department of Clinical Research, SOCAR Research SA, Nyon, Switzerland.; London School of Hygiene and Tropical Medicine, University College London, London, UK.
Macdougall IC; Department of Renal Medicine, King's College Hospital, London, UK.
Metra M; Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Ruschitzka F; Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Kumpeson V; CSL Vifor, Glattbrugg, Switzerland.
Goehring UM; CSL Vifor, Glattbrugg, Switzerland.
van der Meer P; Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Jankowska EA; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.; Institute of Heart Diseases, University Hospital, Wroclaw, Poland.
Pokaż więcej
Corporate Authors:
AFFIRM-AHF investigators
Źródło:
Cardiovascular diabetology [Cardiovasc Diabetol] 2023 Aug 17; Vol. 22 (1), pp. 215. Date of Electronic Publication: 2023 Aug 17.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Diabetes Mellitus*
Heart Failure*/diagnosis
Heart Failure*/drug therapy
Iron Deficiencies*
Humans ; Male ; Iron ; Quality of Life
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial.
Autorzy:
Pagnesi M; Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Adamo M; Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Ter Maaten JM; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Beldhuis IE; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Cotter G; Momentum Research, Inc., Durham, NC, USA.
Davison BA; Momentum Research, Inc., Durham, NC, USA.
Felker GM; Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
Filippatos G; Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Greenberg BH; Division of Cardiology, University of California San Diego, San Diego, CA, USA.
Pang PS; Department of Emergency Medicine, Indiana University School of Medicine and the Regenstrief Institute, Indianapolis, IN, USA.
Ponikowski P; Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Sama IE; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Severin T; Novartis Pharma AG, Basel, Switzerland.
Gimpelewicz C; Novartis Pharma AG, Basel, Switzerland.
Voors AA; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Teerlink JR; Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA.
Metra M; Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2023 Apr; Vol. 25 (4), pp. 541-552. Date of Electronic Publication: 2023 Mar 13.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/complications
Heart Failure*/drug therapy
Mitral Valve Insufficiency*/complications
Humans ; Acute Disease ; Hospitalization ; Stroke Volume ; Ventricular Function, Left
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.
Autorzy:
McEwan P; Health Economics and Outcomes Research Ltd, Cardiff, UK.
Harrison C; Health Economics and Outcomes Research Ltd, Cardiff, UK.
Binnie R; Health Economics and Outcomes Research Ltd, Cardiff, UK.
Lewis RD; Health Economics and Outcomes Research Ltd, Cardiff, UK.
Cohen-Solal A; Hospital Lariboisière, AP-HP, INSERM U948 MASCOT, Université Paris Cité, Paris, France.
Lund LH; Department of Medicine, Karolinska Institutet and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Ohlsson M; Department of Internal Medicine, Malmö University Hospital, Malmö, Sweden.
von Haehling S; Department of Cardiology and Pneumology, University of Göttingen Medical Center and German Center for Cardiovascular Research (DZHK), Göttingen, Germany.
Comin-Colet J; Cardiology Department, Hospital Universitari Bellvitge, University of Barcelona and IDIBELL, Barcelona, Spain.
Pascual-Figal DA; Cardiology Department, Hospital Virgen de la Arrixaca, University of Murcia, Murcia, Spain; and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Wächter S; CSL Vifor, Glattbrugg, Switzerland.
Dorigotti F; CSL Vifor, Glattbrugg, Switzerland.
de Arellano AR; HEOR, CSL Vifor, Glattbrugg, Switzerland.
Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Jankowska EA; Institute of Heart Diseases, University Hospital, Wrocław, Poland.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2023 Mar; Vol. 25 (3), pp. 389-398. Date of Electronic Publication: 2023 Mar 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/drug therapy
Heart Failure*/epidemiology
Heart Failure*/complications
Iron Deficiencies*
Anemia, Iron-Deficiency*/drug therapy
Anemia, Iron-Deficiency*/epidemiology
Anemia, Iron-Deficiency*/complications
Humans ; Patient Discharge ; Cost-Benefit Analysis ; Stroke Volume ; Quality of Life ; Ventricular Function, Left ; Ferric Compounds/therapeutic use ; Hospitalization ; Maltose/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM-HFpEF).
Autorzy:
Linde C; Heart, Vascular and Neurology Theme, Karolinska University Hospital and the Karolinska Institutet, Stockholm, Sweden.
Grabowski M; Department of Cardiology, Medical University of Warsaw, Department of Cardiology, Warsaw, Poland.
Ponikowski P; Impulse Dynamics (USA), Inc, Marlton, NJ, USA.
Rao I; Department of Heart Diseases, Medical University, Wroclaw University Centre for Heart Diseases, University Hospital, Wroclaw, Poland.
Stagg A; Clinical and Data Operations, Impulse Dynamics (USA), Inc, Marlton, NJ, USA.
Tschöpe C; Berlin Institute of Health Center for Regenerative Therapies, and Department of Cardiology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Dec; Vol. 24 (12), pp. 2275-2284. Date of Electronic Publication: 2022 Aug 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/therapy
Humans ; Female ; Aged ; Male ; Stroke Volume ; Pilot Projects ; Prospective Studies ; Ventricular Function, Left ; Health Status
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Machine Learning Approach to Understand Worsening Renal Function in Acute Heart Failure.
Autorzy:
Urban S; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Błaziak M; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Jura M; Department of Physiology and Patophysiology, Wroclaw Medical University, 50-368 Wroclaw, Poland.
Iwanek G; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Ponikowska B; Institute of Heart Diseases, Student Scientific Organization, Wroclaw Medical University, 50-368 Wroclaw, Poland.
Horudko J; Faculty of Electrical Engineering, Warsaw University of Technology, 00-614 Warszawa, Poland.
Siennicka A; Department of Physiology and Patophysiology, Wroclaw Medical University, 50-368 Wroclaw, Poland.
Berka P; Department of Information and Knowledge Engineering, Prague University of Economics and Business, W. Churchill Sq. 1938/4, 130 67 Prague, Czech Republic.
Biegus J; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Zymliński R; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2022 Nov 02; Vol. 12 (11). Date of Electronic Publication: 2022 Nov 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*
Humans ; Acute Disease ; Creatinine ; Kidney/physiology ; Machine Learning
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.
Autorzy:
Inciardi RM; Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Pagnesi M; Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Lombardi CM; Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Anker SD; Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Cleland JG; National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, UK.; Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK.
Dickstein K; University of Bergen, Bergen, Norway.; Stavanger University Hospital, Stavanger, Norway.
Filippatos GS; Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Lang CC; School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK.
Ng LL; Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK.; NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
Pellicori P; Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK.
Ponikowski P; Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Samani NJ; Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK.; NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
Zannad F; Universite de Lorraine, Inserm Centre d'Investigations Cliniques 1433 and F-CRIN INI-CRCT, Nancy, France.
van Veldhuisen DJ; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Solomon SD; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Voors AA; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Metra M; Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Nov; Vol. 24 (11), pp. 2131-2139. Date of Electronic Publication: 2022 Jul 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/drug therapy
Atrial Fibrillation*/complications
Atrial Fibrillation*/drug therapy
Humans ; Female ; Middle Aged ; Aged ; Male ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical determinants and prognostic significance of hypocapnia in acute heart failure.
Autorzy:
Garus M; Institute of Heart Diseases, Medical University, ul. Borowska 213, 50-556, Wroclaw, Poland.
Zdanowicz A; Institute of Heart Diseases, Medical University, ul. Borowska 213, 50-556, Wroclaw, Poland. .
Fudim M; Department of Cardiology, Duke University School of Medicine, Durham, NC, USA.
Zymliński R; Institute of Heart Diseases, Medical University, ul. Borowska 213, 50-556, Wroclaw, Poland.
Niewiński P; Institute of Heart Diseases, Medical University, ul. Borowska 213, 50-556, Wroclaw, Poland.
Paleczny B; Department of Physiology and Pathophysiology, Medical University, Wroclaw, Poland.
Rosiek-Biegus M; Department of Internal Medicine, Pneumology and Allergology, Medical University, Wroclaw, Poland.
Iwanek G; Institute of Heart Diseases, Medical University, ul. Borowska 213, 50-556, Wroclaw, Poland.
Ponikowski P; Institute of Heart Diseases, Medical University, ul. Borowska 213, 50-556, Wroclaw, Poland.
Biegus J; Institute of Heart Diseases, Medical University, ul. Borowska 213, 50-556, Wroclaw, Poland.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Oct 07; Vol. 12 (1), pp. 16889. Date of Electronic Publication: 2022 Oct 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/diagnosis
Hypocapnia*/complications
Acute Disease ; Dyspnea/etiology ; Hospitalization ; Humans ; Hyperventilation ; Lactates ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology.
Autorzy:
Núñez J; Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, Valencia, Spain.; CIBER Cardiovascular, Madrid, Spain.
de la Espriella R; Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, Valencia, Spain.; CIBER Cardiovascular, Madrid, Spain.
Rossignol P; Université de Lorraine, INSERM, Centre d'Investigations Cliniques-Plurithématique 14-33, INSERM U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Voors AA; Department of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Mullens W; Hospital Oost-Limburg, Genk, Belgium.
Metra M; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Cardiology. ASST Spedali Civili, University of Brescia, Brescia, Italy.
Chioncel O; Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', University of Medicine Carol Davila, Bucharest, Romania.
Januzzi JL; Massachusetts General Hospital and Baim Institute for Clinical Research, Boston, MA, USA.
Mueller C; Department of Cardiology, University Hospital, Basel, Switzerland.
Richards AM; Cardiovascular Research Institute, National University of Singapore, Singapore, Singapore.; Christchurch Heart Institute, University of Otago, Dunedin, New Zealand.
de Boer RA; Department of Cardiology University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Thum T; Institute of Molecular and Translational Therapeutic Strategies (IMTTS) and Rebirth Center for Translational Regenerative Therapies, Hannover Medical School, Hannover, Germany.; Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany.
Arfsten H; Clinical Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.
González A; CIBER Cardiovascular, Madrid, Spain.; Program of Cardiovascular Diseases, CIMA Universidad de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Abdelhamid M; Faculty of Medicine, Cairo University, Giza, Egypt.
Adamopoulos S; 2nd Department of Cardiovascular Medicine, Onassis Cardiac Surgery Center, Athens, Greece.
Anker SD; Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Gal TB; Cardiology Department, Rabin Medical Center, Petah Tikva, Israel.
Biegus J; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Cohen-Solal A; Inserm 942 MASCOT, Université de Paris, AP-HP, Hopital Lariboisière, Paris, France.
Böhm M; Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin Homburg/Saar, Saarland University, Saarbrücken, Germany.
Emdin M; Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.; Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
Jankowska EA; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Gustafsson F; Rigshospitalet-Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark.
Hill L; Queen's University Belfast, Belfast, UK.
Jaarsma T; Linkoping University, Linkoping, Sweden.
Jhund PS; BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Lopatin Y; Volgograd State Medical University, Volgograd, Russia.
Lund LH; Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Milicic D; University of Zagreb, School of Medicine, Zagreb, Croatia.
Moura B; Faculty of Medicine, University of Porto, Porto, Portugal.; Cardiology Department, Porto Armed Forces Hospital, Porto, Portugal.
Piepoli MF; Cardiology Division, Castel San Giovanni Hospital, Castel San Giovanni, Italy.
Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Rakisheva A; Scientific Research Institute of Cardiology and Internal Medicine, Almaty, Kazakhstan.
Ristic A; School of Medicine, University of Belgrade, Belgrade, Serbia.
Savarese G; Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Tocchetti CG; Cardio-Oncology Unit, Department of Translational Medical Sciences, Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University, Naples, Italy.
Van Linthout S; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité-Universitätmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.
Volterrani M; IRCCS San Raffaele, Rome, Italy.
Seferovic P; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.; Serbian Academy of Sciences and Arts, Belgrade, Serbia.
Rosano G; St. George's Hospitals NHS Trust University of London, London, UK.
Coats AJS; University of Warwick, Coventry, UK.
Bayes-Genis A; CIBER Cardiovascular, Madrid, Spain.; Institut del Cor, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Oct; Vol. 24 (10), pp. 1751-1766. Date of Electronic Publication: 2022 Sep 07.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/diagnosis
Cardiology*
Humans ; Adrenomedullin ; Prognosis ; Biomarkers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
Autorzy:
Metra M; Insitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Jankowska EA; Institute of Heart Diseases, Wroclaw Medical University, Poland.; Institute of Heart Diseases, University Hospital, Wroclaw, Poland.
Pagnesi M; Insitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Anker SD; Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Germany.
Butler J; University of Mississippi Medical Center, Jackson, MS, USA.
Dorigotti F; Vifor Pharma Ltd, Glattbrugg, Switzerland.
Fabien V; Vifor Pharma Ltd, Glattbrugg, Switzerland.
Filippatos G; National and Kapodistrian University of Athens, School of Medicine, Athens University Hospital Attikon, Department of Cardiology, Athens, Greece.
Kirwan BA; Department of Clinical Research, SOCAR Research SA, Nyon, Switzerland.; London School of Hygiene and Tropical Medicine, University College London, London, UK.
Macdougall IC; Department of Renal Medicine, King's College Hospital, London, UK.
Rosano G; Centre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.
Ruschitzka F; Department of Cardiology, University Heart Center, University Hospital Zürich and University of Zürich, Zürich, Switzerland.
Tomasoni D; Insitute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
van der Meer P; Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, Poland.
Pokaż więcej
Corporate Authors:
AFFIRM-AHF Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Oct; Vol. 24 (10), pp. 1928-1939. Date of Electronic Publication: 2022 Sep 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Iron Deficiencies*
Anemia, Iron-Deficiency*/etiology
Heart Failure*/complications
Heart Failure*/drug therapy
Heart Failure*/chemically induced
Humans ; Male ; Quality of Life ; Maltose ; Ferric Compounds
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology.
Autorzy:
Bayes-Genis A; Institut del Cor, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.; CIBERCV, Carlos III Institute of Health, Madrid, Spain.
Aimo A; Scuola Superiore Sant'Anna, Pisa, Italy.; Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
Jhund P; Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.
Richards M; University of Otago, Dunedin, New Zealand.
de Boer RA; Department of Cardiology, University Medical Centre Groningen, Groningen, The Netherlands.
Arfsten H; Clinical Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Fabiani I; Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
Lupón J; Institut del Cor, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
Anker SD; Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapy (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.
González A; CIBERCV, Carlos III Institute of Health, Madrid, Spain.; Program of Cardiovascular Diseases, CIMA Universidad de Navarra and IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Castiglione V; Scuola Superiore Sant'Anna, Pisa, Italy.
Metra M; Cardiology Department, ASST Spedali Civili; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Mueller C; Department of Cardiology, University Hospital, Basel, Switzerland.
Núñez J; CIBERCV, Carlos III Institute of Health, Madrid, Spain.; Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, Valencia, Spain.
Rossignol P; Academic Hospital (CHU), Nancy, France.
Barison A; Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
Butler J; Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Teerlink J; Heart Failure and of the Echocardiography Laboratory, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
Filippatos G; HF Unit, Attikon University Hospital, Athens, Greece.
Ponikowski P; Centre for Heart Diseases, University Hospital, Wroclaw, Poland.
Vergaro G; Scuola Superiore Sant'Anna, Pisa, Italy.; Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
Zannad F; Université de Lorraine, Centre d'Investigations Cliniques-Plurithématique 1433, and Inserm U1116 CHRU Nancy, F-CRIN INI-CRCT, Nancy, France.
Seferovic P; Department of Cardiology, University Clinical Center of Serbia, Belgrade, Serbia.; Serbian Academy of Sciences and Arts, Belgrade, Serbia.
Rosano G; IRCCS San Raffaele, Rome, Italy.
Coats AJS; University of Warwick, Coventry, UK.
Emdin M; Scuola Superiore Sant'Anna, Pisa, Italy.; Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
Januzzi JL; Massachusetts General Hospital and Baim Institute for Clinical Research, Boston, MA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Oct; Vol. 24 (10), pp. 1767-1777. Date of Electronic Publication: 2022 Sep 20.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Heart Failure*/diagnosis
Heart Failure*/drug therapy
Cardiology*
Humans ; Angiotensin Receptor Antagonists/therapeutic use ; Tetrazoles/therapeutic use ; Aminobutyrates/therapeutic use ; Valsartan/therapeutic use ; Biphenyl Compounds/therapeutic use ; Biomarkers ; Drug Combinations
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF.
Autorzy:
Adamson C; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Cowan LM; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
de Boer RA; Department of Cardiology, University Medical Center and University of Groningen, Groningen, The Netherlands.
Diez M; Division of Cardiology, Institute Cardiovascular de Buenos Aires, Buenos Aires, Argentina.
Drożdż J; Department Cardiology, Medical University of Lodz, Lodz, Poland.
Dukát A; Fifth Department of Internal Medicine, Comenius University in Bratislava, Bratislava, Slovakia.
Inzucchi SE; Section of Endocrinology, Yale School of Medicine, New Haven, CT, USA.
Køber L; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Kosiborod MN; Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City, MO, USA.; The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
Ljungman CEA; Institute of Medicine, Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Martinez FA; Universidad Nacional de Córdoba, Córdoba, Argentina.
Ponikowski P; Center for Heart Diseases, University Hospital, Wroclaw Medical University, Wroclaw, Poland.
Sabatine MS; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Lindholm D; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Bengtsson O; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Boulton DW; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
Greasley PJ; Early Research and Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Langkilde AM; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Sjöstrand M; Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Solomon SD; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Jhund PS; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Oct; Vol. 24 (10), pp. 1856-1868. Date of Electronic Publication: 2022 Aug 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*
Humans ; Stroke Volume ; Ventricular Function, Left ; Bilirubin ; Liver
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC).
Autorzy:
Metra M; Cardiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Chioncel O; Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania.; University of Medicine Carol Davila, Bucharest, Romania.
Cotter G; Momentum Research, Inc, Chapel Hill, NC, USA.; Cardiovascular Markers in Stress Conditions (MASCOT), Université Paris Cité; Inserm UMR-S 942, Paris, France.
Davison B; Momentum Research, Inc, Chapel Hill, NC, USA.; Cardiovascular Markers in Stress Conditions (MASCOT), Université Paris Cité; Inserm UMR-S 942, Paris, France.
Filippatos G; Department of Cardiology, University of Cyprus, School of Medicine & National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece.
Mebazaa A; Cardiovascular Markers in Stress Conditions (MASCOT), Université Paris Cité; Inserm UMR-S 942, Paris, France.; Department of Anesthesiology and Critical Care and Burn Unit, Hôpital Saint-Louis Lariboisière, FHU PROMICE, DMU Parabol, APHP.Nord, Paris, France.
Novosadova M; Momentum Research, Inc, Chapel Hill, NC, USA.
Ponikowski P; Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.
Simmons P; Windtree Therapeutics, Inc., Warrington, PA, USA.
Soffer J; Windtree Therapeutics, Inc., Warrington, PA, USA.
Simonson S; Windtree Therapeutics, Inc., Warrington, PA, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Oct; Vol. 24 (10), pp. 1967-1977. Date of Electronic Publication: 2022 Aug 22.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/complications
Heart Failure*/drug therapy
Humans ; Shock, Cardiogenic/drug therapy ; Shock, Cardiogenic/etiology ; Cardiotonic Agents/therapeutic use ; Etiocholanolone/therapeutic use ; Double-Blind Method
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
Autorzy:
Voors AA; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Damman K; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Teerlink JR; Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA.
Angermann CE; Comprehensive Heart Failure Centre, University & University Hospital of Würzburg, Würzburg, Germany.
Collins SP; Department of Emergency Medicine, Vanderbilt University Medical Center and Geriatric Research and Education Clinical Care, Tennessee Valley Healthcare Facility VA Medical Center, Nashville, TN, USA.
Kosiborod M; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MS, USA.; The George Institute for Global Health and The University of New South Wales, Sydney, NSW, Australia.
Biegus J; Institute of Heart Diseases, Medical University, Wroclaw, Poland.
Ferreira JP; Inserm INI-CRCT, CHRU, Université de Lorraine, Nancy, France.; Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
Nassif ME; Saint Luke's Mid America Heart Institute and the University of Missouri, Kansas City, MS, USA.
Psotka MA; Inova Heart and Vascular Institute, Falls Church, VA, USA.
Tromp J; Saw Swee Hock School of Public Health, National University of Singapore, and the National University Health System, Singapore.
Brueckmann M; Boehringer Ingelheim International GmbH, Ingelheim, Germany.; First Department of Medicine faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
Blatchford JP; Elderbrook Solutions GmbH on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Salsali A; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.; Faculty of Medicine, Rutgers University, New Brunswick, NJ, USA.
Ponikowski P; Institute of Heart Diseases, Medical University, Wroclaw, Poland.
Pokaż więcej
Corporate Authors:
EMPULSE Trial Investigators
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Oct; Vol. 24 (10), pp. 1844-1852. Date of Electronic Publication: 2022 Sep 27.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Sodium-Glucose Transporter 2 Inhibitors*/pharmacology
Diabetes Mellitus, Type 2*/drug therapy
Heart Failure*
Humans ; Quality of Life ; Kidney ; Hospitalization
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports.
Autorzy:
Urban S; Institute of Heart Diseases, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Fułek M; Department of Internal Medicine, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Błaziak M; Institute of Heart Diseases, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Iwanek G; Institute of Heart Diseases, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Jura M; Department of Physiology and Pathophysiology, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Fułek K; Lower Silesian Oncology, Pulmonology and Hematology Center, 50-376 Wroclaw, Poland.
Guzik M; Institute of Heart Diseases, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Garus M; Institute of Heart Diseases, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Gajewski P; Institute of Heart Diseases, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Lewandowski Ł; Department of Medical Biochemistry, Wroclaw Medical University, Chalubinskiego 10, 50-368 Wroclaw, Poland.
Biegus J; Institute of Heart Diseases, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Trzeciak P; 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Tycińska A; Department of Cardiology, Medical University of Bialystok, 15-089 Bialystok, Poland.
Zymliński R; Institute of Heart Diseases, Wroclaw Medical University, 50-376 Wroclaw, Poland.
Pokaż więcej
Źródło:
Journal of clinical medicine [J Clin Med] 2022 Sep 21; Vol. 11 (19). Date of Electronic Publication: 2022 Sep 21.
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
Autorzy:
Senni M; University of Milan - Bicocca, Milan, ASST Papa Giovanni XXIII, Bergamo, Italy.
Alemayehu WG; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
Sim D; National Heart Centre, Singapore, Singapore.
Edelmann F; Charite Universitätsmedizin, Berlin, Germany.
Butler J; University of Mississippi Medical Center, Jackson, MS, USA.
Ezekowitz J; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
Hernandez AF; Duke Clinical Research Institute, Durham, NC, USA.
Lam CSP; National Heart Centre, Singapore, Singapore.
O'Connor CM; Inova Heart and Vascular Institute, Falls Church, VA, USA.
Pieske B; Charite Universitätsmedizin, Berlin, Germany.
Ponikowski P; Wroclaw Medical University, Wroclaw, Poland.
Roessig L; Bayer AG, Wuppertal, Germany.
Voors AA; University Medical Center Groningen, Groningen, The Netherlands.
Westerhout CM; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
McMullan C; Merck & Co., Inc., Kenilworth, NJ, USA.
Armstrong PW; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
Pokaż więcej
Corporate Authors:
VICTORIA Study Group
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Sep; Vol. 24 (9), pp. 1614-1622. Date of Electronic Publication: 2022 Jul 20.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/drug therapy
Heterocyclic Compounds, 2-Ring*/adverse effects
Pyrimidines*/adverse effects
Ventricular Dysfunction, Left*/drug therapy
Aminobutyrates/therapeutic use ; Biphenyl Compounds/therapeutic use ; Drug Combinations ; Humans ; Hyperkalemia/epidemiology ; Hypotension/epidemiology ; Stroke Volume/physiology ; Treatment Outcome ; Valsartan/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Novel Therapeutic Devices in Heart Failure.
Autorzy:
Guzik M; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Urban S; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Iwanek G; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Biegus J; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Zymliński R; Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Pokaż więcej
Źródło:
Journal of clinical medicine [J Clin Med] 2022 Jul 25; Vol. 11 (15). Date of Electronic Publication: 2022 Jul 25.
Typ publikacji:
Journal Article; Review
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
Autorzy:
McDowell K; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Welsh P; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Docherty KF; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Morrow DA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Jhund PS; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
de Boer RA; Department of Cardiology, University Medical Center and University of Groningen, Groningen, The Netherlands.
O'Meara E; Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
Inzucchi SE; Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
Køber L; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Kosiborod MN; Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City, MO, USA.; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Martinez FA; Universidad Nacional de Córdoba, Córdoba, Argentina.
Ponikowski P; Centre for Heart Diseases, University Hospital, Wroclaw Medical University, Wroclaw, Poland.
Hammarstedt A; Late Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, Astrazeneca, Gothenburg, Sweden.
Langkilde AM; Late Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, Astrazeneca, Gothenburg, Sweden.
Sjöstrand M; Late Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, Astrazeneca, Gothenburg, Sweden.
Lindholm D; Late Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, Astrazeneca, Gothenburg, Sweden.
Solomon SD; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Sattar N; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Sabatine MS; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 Jun; Vol. 24 (6), pp. 1066-1076. Date of Electronic Publication: 2022 Feb 06.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Heart Failure*/complications
Ventricular Dysfunction, Left*/complications
Aged ; Benzhydryl Compounds ; Female ; Glucosides/pharmacology ; Humans ; Male ; Middle Aged ; Stroke Volume ; Uric Acid
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
Autorzy:
Anker SD; Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Center for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.; Institute of Heart Diseases, University Hospital in Wroclaw, Poland.
Ponikowski P; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Khan MS; Division of Cardiology, Duke University Medical Center, Durham, NC, USA.
Friede T; Göttingen, Germany; DZHK (German Center for Cardiovascular Research), Göttingen partner site, University Medical Center Göttingen, Göttingen, Germany.
Jankowska EA; Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Fabien V; Vifor Pharma Ltd., Glattbrugg, Switzerland.
Goehring UM; Vifor Pharma Ltd., Glattbrugg, Switzerland.
Metra M; Cardiology, University and Civil Hospital, Brescia, Italy.
Piña IL; Central Michigan University, Mount Pleasant, MI, USA.
Coats AJS; University of Warwick, Coventry, UK.
Rosano G; Centre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.
Dorigotti F; Vifor Pharma Ltd., Glattbrugg, Switzerland.
Comin-Colet J; Department of Cardiology, Bellvitge University Hospital; IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.
Van Veldhuisen DJ; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Filippatos GS; Medical School University of Cyprus, Nicosia, Cyprus.; School of Medicine of National and Kapodistrian University of Athens, Athens University Hospital Attikon, Athens, Greece.
Butler J; Department of Medicine, University of Mississippi, Jackson, MS, USA.
Pokaż więcej
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 May; Vol. 24 (5), pp. 833-842. Date of Electronic Publication: 2022 Apr 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anemia, Iron-Deficiency*/drug therapy
Heart Failure*/drug therapy
Iron Deficiencies*
Ventricular Dysfunction, Left*/drug therapy
Ferric Compounds ; Humans ; Iron/therapeutic use ; Maltose/analogs & derivatives ; Maltose/therapeutic use ; Stroke Volume ; Treatment Outcome ; Walk Test
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.
Autorzy:
Saldarriaga C; Department of Cardiology, University of Antioquia, CardioVID Clinic, Medellín, Colombia.
Atar D; Department of Cardiology, Oslo University Hospital Ulleval, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Stebbins A; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Lewis BS; Lady Davis Carmel Medical Center, Haifa, Israel.
Abidin IZ; UM Specialist Centre, Kuala Lumpur, Malaysia.
Blaustein RO; Merck & Co. Inc., Kenilworth, NJ, USA.
Butler J; University of Mississippi Medical Center, Jackson, MS, USA.
Ezekowitz JA; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Lam CSP; National Heart Centre Singapore & Duke-National University of Singapore, Singapore.
O'Connor CM; Inova Heart and Vascular Institute, Falls Church, VA, USA.
Pieske B; Charité University Medicine, German Heart Center, Berlin, Germany.
Ponikowski P; Wroclaw Medical University, Wroclaw, Poland.
Roessig L; Bayer AG, Wuppertal, Germany.
Voors AA; University of Groningen, Groningen, The Netherlands.
Anstrom KJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Armstrong PW; Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
Pokaż więcej
Corporate Authors:
VICTORIA Study Group
Źródło:
European journal of heart failure [Eur J Heart Fail] 2022 May; Vol. 24 (5), pp. 782-790. Date of Electronic Publication: 2022 Mar 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Coronary Artery Disease*/complications
Coronary Artery Disease*/drug therapy
Heart Failure*/complications
Heart Failure*/epidemiology
Heart Failure*/therapy
Heterocyclic Compounds, 2-Ring*/therapeutic use
Ventricular Dysfunction, Left*/drug therapy
Humans ; Male ; Pyrimidines ; Stroke Volume
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 212

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies